Immunocore reports first quarter financial results and provides a business update

Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: KIMMTRAK doubles likelihood of being alive at five years for patients with HLA-A*02:01 positive metastatic uveal melanoma Cash, cash equivalents and marketable securities of $845 million as of March 31, 2026 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.

GlobeNewsWire • May 6, 2026

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

GlobeNewsWire • Apr 19, 2026

Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference

Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.

GlobeNewsWire • Apr 6, 2026

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn.

GlobeNewsWire • Mar 17, 2026

Immunocore to present at upcoming investor conferences

Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.

GlobeNewsWire • Mar 3, 2026

Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript

Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 25, 2026

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; expect moderating revenue growth in 2026 TEBE-AM enrollment completion anticipated 1H 2026 with topline data expected as early as 2H 2026 PRAME franchise Phase 1/2 data to be presented in 2H 2026: brenetafusp in ovarian and lung cancer, and initial data with half-life extended candidate (IMC-P115C) Additional Phase 1 HIV data to be presented in 2H 2026 Cash, cash equivalents and marketable securities of $864.2 million as of December 31, 2025 Conference call today, February 25 at 8:00AM ET, 1:00 PM GMT (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.

GlobeNewsWire • Feb 25, 2026

Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025

Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.

GlobeNewsWire • Feb 18, 2026

Immunocore (IMCR) Upgraded to Strong Buy: Here's Why

Immunocore (IMCR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Feb 17, 2026

Immunocore announces R&D leadership evolution

Immunocore announces R&D leadership evolution Dr. David Berman will depart the Company Dr. Mohammed Dar, Chief Medical Officer, and Mark Moyer, Head of Regulatory Sciences, promoted to Executive Vice President roles (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.

GlobeNewsWire • Jan 30, 2026